New hope for hard-to-treat colon cancer: drug combo targets RAS mutation
Disease control
ENROLLING_BY_INVITATION
This study tests a new drug called XS-03 combined with standard chemotherapy and a targeted therapy (bevacizumab) in people with metastatic colorectal cancer that has a RAS mutation. About 102 adults aged 18-70 will take part. The goal is to see if the combination is safe and wor…
Phase: PHASE1, PHASE2 • Sponsor: NovaOnco Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 10:28 UTC